Price to earnings forward of Nurix Therapeutics, Inc. – NASDAQ:NRIX
This article displays financial information for Nurix Therapeutics, Inc. (NASDAQ: NRIX), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, indicating that the market is currently closed with no trades.
NRIX - Nurix Therapeutics Inc Volatility & Greeks
This page provides an overview of Nurix Therapeutics Inc (NRIX) stock, detailing its volatility and "Greeks" (option-related metrics not explicitly listed but implied by the title) alongside comprehensive financial data. It includes key metrics such as market capitalization, income, sales, EPS, various financial ratios, insider and institutional ownership, and performance indicators across different timeframes. The information is presented as a snapshot of the company's financial health and stock performance.
NRIX - Nurix Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Nurix Therapeutics Inc. (NRIX). It includes key financial metrics, performance indicators, insider ownership details, and analyst recommendations, offering a detailed snapshot of the company's current financial health and market position.
Nurix (NRIX) Chief Legal Officer exercises options and sells 11,008 shares
Nurix Therapeutics' Chief Legal Officer, Christine Ring, executed an option exercise-and-sale transaction, acquiring and then selling 11,008 shares of company stock. The transaction involved exercising stock options at $1.86 and $8.72 per share and selling them in the open market at a weighted average price of $23.5616 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Ms. Ring directly holds 13,579 shares and retains an option for 128,611 shares.
Nurix Therapeutics CLO Christine Ring sells $259,366 in stock
Christine Ring, CLO of Nurix Therapeutics, sold $259,366 worth of company stock through a pre-arranged trading plan. This sale followed her acquisition of an equivalent number of shares via employee stock options. The transactions occurred while the stock was trading near its 52-week high, and an InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value.
Nurix Therapeutics CLO Christine Ring sells $259,366 in stock By Investing.com
Christine Ring, CLO of Nurix Therapeutics (NASDAQ:NRIX), sold $259,366 worth of company stock on July 2, 2026, as part of a pre-arranged 10b5-1 trading plan. The sale followed the exercise of employee stock options and comes after a significant 93% gain in the stock over the past year, though InvestingPro analysis suggests it may be overvalued. Nurix also announced positive clinical trial results for its BTK degrader and a collaboration with Roche, leading to reiterated favorable analyst ratings.
Form 4 Nurix Therapeutics Inc For: 2 July By Investing.com
This article provides details of a Form 4 filing for Nurix Therapeutics Inc. dated July 2, 2026. Form 4 filings are used to declare changes in beneficial ownership of securities by company insiders. The article includes the company's stock ticker (NRIX) and its recent percentage change.
Pictet Asset Management Holding SA Sells 741,462 Shares of Nurix Therapeutics, Inc. $NRIX
Pictet Asset Management Holding SA reduced its stake in Nurix Therapeutics (NASDAQ:NRIX) by 21.4% in the first quarter, selling 741,462 shares and retaining 2.73 million shares valued at $42.3 million. This comes as Nurix Therapeutics reported a quarterly loss of $0.79 per share and revenue of $6.25 million, both missing analyst expectations, with full-year loss projected at $2.83 EPS. Despite mixed financials, analysts maintain a "Moderate Buy" rating with an average target price of $32.20, and several firms have raised their price targets.
Roche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseases
Roche and Nurix Therapeutics have partnered to co-develop and co-commercialize bexobrutideg, an investigational Bruton’s Tyrosine Kinase (BTK) degrader. This collaboration aims to create a best-in-class targeted protein degrader for B-cell malignancies, as well as indications in immunology and neurology like chronic spontaneous urticaria and multiple sclerosis. Bexobrutideg works by degrading the BTK protein, offering potential advantages over current BTK inhibitors by overcoming resistance and providing more durable pathway suppression.
Top 3 Health Care Stocks That May Keep You Up At Night In June
This article identifies three healthcare stocks—Definium Therapeutics (DFTX), Nurix Therapeutics (NRIX), and Galectin Therapeutics (GALT)—that are considered overbought based on their high Relative Strength Index (RSI) values and recent price performance. Definium Therapeutics saw a significant gain after a public offering, Nurix Therapeutics received an upgraded price target from an analyst, and Galectin Therapeutics surged after positive feedback from the FDA. Investors who prioritize momentum in their trading decisions are cautioned about these steeply valued stocks.
Nurix Therapeutics (NRIX) Is Up 30.5% After Landmark Roche BTK Degrader Collaboration - What's Changed
Nurix Therapeutics' stock jumped 30.5% following a landmark collaboration with Roche for its BTK degrader, bexobrutideg, involving a $700 million upfront payment and up to $2.30 billion in milestones. This partnership provides significant funding, reduces financial pressure, and leverages Roche's global capabilities, reshaping Nurix's investment narrative. Despite this, core risks remain, including unprofitability, high R&D spending, and concentration on a single clinical asset, which investors must consider alongside a potentially high valuation.
Nurix Therapeutics (NRIX) Is Up 30.5% After Landmark Roche BTK Degrader Collaboration - What's Changed
Nurix Therapeutics (NRIX) experienced a significant 30.5% stock increase following its landmark collaboration with Roche. The partnership involves co-developing and co-commercializing bexobrutideg, an oral BTK degrader, providing Nurix with a US$700 million upfront payment and up to US$2.30 billion in milestones. This deal substantially strengthens Nurix's balance sheet and reduces immediate financing pressures, although the company still faces risks associated with profitability and its reliance on a single clinical asset.
5 Best Biotech Stocks to Buy According to Analysts
This article highlights Nurix Therapeutics, Inc. (NASDAQ:NRIX) as one of the best biotech stocks to buy, according to analysts. Baird recently increased its price target for NRIX to $33, maintaining an Outperform rating, due to its partnership with Roche and advancements in clinical programs. The company also reported positive updated clinical findings for its investigational drug bexobrutideg, showing durable responses and a favorable safety profile in patients with chronic lymphocytic leukemia.
Is Nurix Therapeutics (NRIX) Overvalued As Its Roche Deal Lifts Hopes For Future Growth?
Nurix Therapeutics (NRIX) stock has seen significant momentum following a collaboration deal with Roche for bexobrutideg, leading to a substantial share price increase and new 52-week highs. Despite the positive news, the article raises concerns about the company's valuation, noting a high Price-to-Sales ratio of 33x compared to the broader biotech industry, and ongoing net losses. While the Roche deal lifts hopes, the article suggests the stock may be overvalued and highlights key risks and mixed sentiment among investors.
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) experienced a significant 16.4% stock increase, closing at $22.46, driven by investor optimism following a collaboration agreement with Roche. Under this deal, Nurix will receive $700 million upfront and up to $2.3 billion in milestone payments for co-developing bexobrutideg. Analysts have revised quarterly EPS estimates for Nurix 1.8% higher, suggesting potential for further stock appreciation.
Nurix Stock Up 29% in a Month: Here's What You Should Know
Nurix Therapeutics (NRIX) stock has increased by 29% in the past month, driven by a new collaboration with Roche (RHHBY). This agreement, worth up to $3 billion, focuses on co-developing bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader for various hematology, immunology, and neurology indications. Bexobrutideg, which eliminates rather than just inhibits BTK, is expected to enter phase III trials for chronic lymphocytic leukemia in 2026 and plans phase II studies for multiple sclerosis and chronic spontaneous urticaria.
Nurix Therapeutics CLO Christine Ring sells $580,505 in shares
Christine Ring, Chief Legal Officer at Nurix Therapeutics, Inc. (NRIX), sold 28,935 shares of the company's common stock for $580,505 on June 25, 2026, pursuant to a pre-arranged trading plan. She also acquired 28,935 shares through option exercises for a total cost of $232,847. These transactions occurred as the stock trades near its 52-week high and appears overvalued, despite positive analyst reactions to recent clinical trial results and a significant collaboration with Roche.
Nurix (NRIX) CSO executes pre-planned sale of 5,394 shares at $20
Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, executed a pre-planned sale of 5,394 shares of Common Stock at $20.00 per share. This transaction was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not a discretionary sale. Following the sale, Hansen still retains a substantial direct holding of 115,005 shares, suggesting a routine liquidity event rather than a change in insider sentiment.
Nurix therapeutics CSO Gwenn Hansen sells $107,880 in stock
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NASDAQ:NRIX), sold 5,394 shares of common stock for $107,880 on June 25, 2026, at a price of $20.0 per share. This sale was conducted under a Rule 10b5-1 trading plan. Following the transaction, Ms. Hansen directly owns 115,005 shares, while the stock has seen a significant 93% gain over the past year and analysts maintain positive ratings due to recent clinical trial updates and a collaboration with Roche.
Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer
Nurix Therapeutics Inc. (NASDAQ:NRIX) reached a new 52-week high after extending gains for an eighth consecutive session. This surge follows a partnership announcement with Roche for the co-development and commercialization of bexobrutideg, a potential best-in-class oral degrader for Bruton’s tyrosine kinase (BTK). Nurix is set to receive $700 million upfront and up to $2.3 billion in milestone payments from this deal.
Form 4 Nurix Therapeutics Inc For: 25 June By Investing.com
This article from Investing.com announces the filing of Form 4 for Nurix Therapeutics Inc. on June 25. It briefly mentions the company's stock symbol NRIX and its stock performance on the day. The article is very concise and primarily serves as a notification regarding the Form 4 filing.
Nurix Therapeutics, Inc. Actuals & Estimates (NASDAQ:NRIX)
This article provides a comprehensive overview of Nurix Therapeutics, Inc. (NASDAQ: NRIX) stock, including its current price, historical performance, analyst forecasts, and financial data. It details key metrics such as market capitalization, volatility, earnings, revenue, and EBITDA, while also offering information on the company's employee count and upcoming earnings release date.
NRIX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Nurix Therapeutics, Inc. (NRIX) stock, indicating a consensus price target of $31.44 from 16 analysts, with a max estimate of $45.00 and a min of $23.00. It also outlines recent stock performance, financial metrics like market capitalization and net income, upcoming earnings dates, and general investment advice. The article emphasizes the importance of personal research before making investment decisions.
Flax Pond Capital LLC Invests $1.52 Million in Nurix Therapeutics, Inc. $NRIX
Flax Pond Capital LLC has invested $1.52 million in Nurix Therapeutics (NASDAQ:NRIX), purchasing 80,200 shares. Despite some positive analyst revisions, including increased price targets from Truist, BTIG, and Jefferies, the company recently reported weaker-than-expected earnings and has seen insider selling. Nurix Therapeutics holds a consensus "Moderate Buy" rating with a target price of $32.20, but its stock currently trades below its 52-week high.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from Brokerages
Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average "Moderate Buy" rating from brokerages, with 14 out of 16 analysts recommending the stock and a consensus 12-month price target of $32.20. While analysts like Truist, Jefferies, and Needham reiterated bullish views, Wells Fargo downgraded the stock to hold. The company recently missed Q1 earnings expectations, reporting an EPS of -$0.79 against an anticipated -$0.76 and revenues of $6.25 million against $14.25 million expected.
Nurix Therapeutics (NRIX) Q4 2025 earnings summary
Nurix Therapeutics announced its Q4 2025 earnings, highlighting the initiation of the pivotal DAYBreak Phase 2 study for bexobrutideg in CLL and strong financial results, including $84.0M in full-year revenue. The company also strengthened its balance sheet with a $250M equity offering, ending the year with $592.9M in cash, and plans to advance its pipeline with ongoing clinical trials and collaborations.
Roche–Nurix Bexobrutideg Alliance Might Change The Case For Investing In Nurix Therapeutics (NRIX)
Nurix Therapeutics recently announced an exclusive worldwide licensing and collaboration agreement with Roche for its drug bexobrutideg, including a significant upfront payment and potential total deal value. This partnership, which involves shared development costs and U.S. profit split, is expected to transform bexobrutideg from a single-asset cancer program into a multi-indication franchise candidate. The alliance shifts Nurix's investment narrative, reducing financing risk but increasing clinical and regulatory execution risk for the drug.
Perceptive Advisors LLC Buys 2,139,728 Shares of Nurix Therapeutics, Inc. $NRIX
Perceptive Advisors LLC significantly increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 151.1% in the fourth quarter, purchasing 2.14 million additional shares and bringing its total holding to 3.56 million shares. Despite this institutional buying and a "Moderate Buy" consensus rating from analysts, company insiders have been selling shares, and Nurix Therapeutics recently missed EPS and revenue estimates.
Nurix Therapeutics Inc (NRIX) Institutional Confidence
Nurix Therapeutics Inc (NRIX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership accounts for 118.09% of shares outstanding, a significant increase from the previous quarter. Key institutional holders include Redmile Group, LLC, BlackRock Institutional Trust Company, N.A., and Deep Track Capital LP, with varying changes in their holdings.
Nurix Therapeutics Inc (NRIX) Valuation: PE, PB & Fair Value Analysis
Nurix Therapeutics Inc (NRIX) currently has a valuation score of 6.93, placing it 283rd out of 388 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -5.40, which is significantly below its recent high and above its recent low. However, key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
General Atlantic L.P. Buys Shares of 4,897,159 Nurix Therapeutics, Inc. $NRIX
General Atlantic L.P. has acquired a significant new stake of 4,897,159 shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the fourth quarter, valued at approximately $92.9 million. This makes Nurix the firm's 9th largest holding and represents about 4.76% of Nurix's total shares. Other institutional investors like Morgan Stanley, Pictet Asset Management, and Vanguard Group Inc. also increased their positions in the company, despite Nurix reporting a wider-than-expected quarterly EPS loss of $0.79 on revenues of $6.25 million.
Nurix Therapeutics Inc (NRIX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Nurix Therapeutics Inc (NRIX), listing its major shareholders and their proportional holdings, such as Redmile Group, LLC and BlackRock Institutional Trust Company, N.A. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and provides a historical overview of institutional shareholding and activity. Additionally, the article identifies several ETFs that include NRIX in their portfolios.
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Truist analyst Gregory Renza raised Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) price target to $32 from $30, maintaining a "Buy" rating. This optimistic outlook follows a strategic partnership between Nurix and Roche, valued at up to $2.3 billion, for the blood cancer drug bexobrutideg. The deal, which includes a $700 million upfront payment, validates bexobrutideg's clinical potential and strengthens Nurix's financial position, with Phase III trials for the drug expected to begin soon.
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination
The article discusses the significant momentum in the biotech sector, highlighting three companies: Nurix Therapeutics, BioNxt Solutions, and Zealand Pharma. Nurix secured a major partnership with Roche for its BTK protein degrader, involving substantial upfront payments and future revenue sharing. BioNxt Solutions is advancing its sublingual thin-film technology into the GLP-1 market for obesity and diabetes, with its semaglutide program entering active development. Zealand Pharma faced a stock downturn due to severe gastrointestinal side effects of its obesity drug survodutide, despite its high efficacy, necessitating plans for improved tolerability and positioning.
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
Nurix Therapeutics announced updated Phase 1a/b clinical trial data for bexobrutideg, an oral BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The results highlight durable responses, with an 83% objective response rate and 22.1 months median progression-free survival in heavily pretreated relapsed/refractory CLL/SLL patients and promising activity in earlier lines of therapy. Bexobrutideg demonstrated a high objective response rate of 92.9% in second-line patients who progressed on BTK inhibitors and was well-tolerated across cohorts, reinforcing its potential as a best-in-class treatment.
Nurix (NRIX) presents updated Bexobrutideg data at EHA 2026
Nurix Therapeutics released updated Phase 1a/b clinical data for its experimental leukemia drug, bexobrutideg, showing sustained efficacy and high response rates in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Despite these positive results, Nurix shares fell due to concerns about the company's long-term capital expenditure commitments for advancing the drug to late-stage studies, as Nurix is responsible for 40% of global clinical trial costs in its collaboration with Roche. The drug demonstrated an 83% objective response rate in heavily pretreated patients and 92.9% in second-line patients, with a favorable safety profile.
Nurix Highlights Promising Phase 1b Data for Bexobrutideg
Nurix Therapeutics reported encouraging Phase 1a/1b clinical data for its oral BTK degrader bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug demonstrated good safety and high objective response rates, even in heavily pretreated and earlier-line settings. This data supports Nurix's plans to advance bexobrutideg into broader late-stage development and suggests its potential as a best-in-class BTK-directed therapy.
Nurix Therapeutics reports Phase 1a/1b update: 83% ORR, 22.1-month median PFS; 600 mg RP2D well tolerated
Nurix Therapeutics (NRIX) reported updated positive Phase 1a/1b data for bexobrutideg, showing an 83% Overall Response Rate (ORR) and a median Progression-Free Survival (PFS) of 22.1 months. The 600 mg RP2D dose was well tolerated in 86 patients, with common adverse events being manageable. Subgroups including BTKi-treated and BTKi-naïve patients also demonstrated high ORR.
Nurix (NASDAQ: NRIX) shows high CLL response rates in bexobrutideg Phase 1
Nurix Therapeutics released updated Phase 1a/1b clinical data for its oral BTK degrader, bexobrutideg (NX-5948), in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug demonstrated high objective response rates, including 83.0% in heavily pretreated Phase 1a patients and over 84% in earlier-line Phase 1b cohorts, with a favorable safety profile. These results support advancing bexobrutideg into a broad Phase 3 monotherapy program and exploring combination regimens.
Nurix Therapeutics Inc
Swiss pharmaceutical giant Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, which could be worth up to $2.3 billion. This deal focuses on cancer drug development. The announcement was made on a Monday.
Amova Asset Management Americas Inc. Has $24.48 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX
Amova Asset Management Americas Inc. reduced its stake in Nurix Therapeutics (NASDAQ:NRIX) by 17.1% in Q4, but still holds 1.29 million shares valued at $24.48 million. Despite this reduction, other major investors like Deutsche Bank, Goldman Sachs, and Geode Capital increased their positions, indicating sustained institutional interest. Nurix Therapeutics reported a wider-than-expected loss and lower revenue in its latest earnings, yet analysts maintain a "Moderate Buy" consensus with an average price target of $32.14.
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Nurix Therapeutics has seen a significant stock increase following its collaboration with Roche Holdings AG to co-develop and co-commercialize bexobrutideg, a BTK degrader targeting B-cell malignancies. This partnership involves an upfront payment of $700 million to Nurix and potential milestones up to $2.3 billion, with shared development costs and profit-sharing for U.S. commercialization. The stock is currently showing strong bullish momentum, trading above its key simple moving averages.
Nurix Therapeutics (NASDAQ:NRIX) Sees Unusually-High Trading Volume After Analyst Upgrade
Nurix Therapeutics (NRIX) experienced unusually high trading volume after BTIG Research raised its price target from $30 to $32, maintaining a "buy" rating. This upgrade follows a broad improvement in analyst sentiment due to Nurix's collaboration with Roche, involving a $700 million upfront payment. Despite widespread positive sentiment and increased price targets from several firms, some analysts remain cautious, with Wells Fargo downgrading the stock to "hold" and recent insider sales and an earnings miss also contributing to mixed signals.
Nurix surges 43% on up to $3B cancer drug deal with Roche
Nurix Therapeutics announced a significant collaboration with Roche, potentially valued at up to $3 billion, to develop and commercialize targeted protein degradation drugs for cancer. This deal includes an upfront payment of $120 million to Nurix. Following the news, Nurix's shares surged by 43%.
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics
Swiss pharmaceutical company Roche has secured an exclusive licensing and collaboration agreement with Nurix Therapeutics, potentially worth up to $2.3 billion. The deal focuses on bexobrutideg, a blood cancer drug designed to degrade targeted proteins, which is slated to begin a phase III clinical trial for chronic lymphocytic leukaemia this summer. Nurix will receive an upfront payment of $700 million, with additional payouts contingent on development, regulatory, and sales milestones.
Nurix Therapeutics Stock Pops on Roche Partnership
Nurix Therapeutics (NRIX) stock surged 15.7% after announcing a collaboration and licensing agreement with Roche for a blood cancer treatment. The deal includes a $700 million upfront payment and up to $1.6 billion in additional milestone payments, with joint commercialization planned in the United States. This news helped NRIX break a five-day losing streak and recover some of its year-to-date deficit, with some gains potentially attributed to short covering.
Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics
Roche has entered into a licensing and collaboration agreement with Nurix Therapeutics for bexobrutideg, a BTK-degrader developed for blood cancers and other diseases. The deal is valued at up to $2.3 billion, with an upfront payment of $700 million to Nurix, and includes co-commercialization rights in the US and global marketing rights for Roche. Bexobrutideg is expected to outperform existing BTK inhibitors by degrading the protein rather than just inhibiting it, potentially overcoming drug resistance and offering a best-in-class treatment option.
Nurix (NASDAQ: NRIX) lands $700M Roche bexobrutideg pact with up to $2.3B
Nurix Therapeutics has entered into a global collaboration agreement with Roche for its investigational oral BTK degrader, bexobrutideg (NX-5948). The deal includes an upfront payment of $700 million to Nurix and potential milestone payments of up to $2.3 billion. The companies will co-develop and co-commercialize bexobrutideg in the U.S., sharing costs and profits, while Roche will commercialize ex-U.S. with Nurix receiving tiered royalties.
Nurix Therapeutics and Roche Announce Strategic Collaboration to Develop Bexobrutideg for B-Cell Malignancies and Beyond
Nurix Therapeutics has entered a global collaboration with Roche to develop and commercialize bexobrutideg, an oral degrader of Bruton’s tyrosine kinase (BTK), for B-cell malignancies and other immune-mediated diseases. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in milestone payments, with shared development costs and profits in the U.S. This partnership aims to leverage Nurix's expertise in targeted protein degradation and Roche's commercial capabilities to address significant unmet medical needs.
Roche announces global collaboration with Nurix
Roche has announced a global collaboration with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader, across malignant hematology, immunology, and neurology. Nurix will receive an upfront payment of $700 million and is eligible for up to $2.3 billion in development, regulatory, and sales milestones. This partnership aims to leverage bexobrutideg's potential as a best-in-class treatment, and clinical development for CLL is expected to initiate a Phase 3 trial in summer 2026.
